{"name":"Fulcrum Therapeutics","slug":"fulcrum","ticker":"FULC","exchange":"NASDAQ","domain":"fulcrumtx.com","description":"Fulcrum Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases and neuromuscular disorders. The company's pipeline includes several promising candidates, including Loxo-305 for facioscapulohumeral muscular dystrophy (FSHD). With a strong focus on innovation and collaboration, Fulcrum Therapeutics is well-positioned to make a meaningful impact in the rare disease space.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Robert Gould","sector":"Rare Disease / Neuromuscular","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$280M","metrics":{"revenue":8000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":56103000,"netIncome":-74880000,"cash":366284000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"FULC Announces FDA Fast Track Designation for Loxo-305","summary":"Fulcrum Therapeutics announced that the FDA has granted Fast Track designation to Loxo-305 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).","drugName":"Loxo-305","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"FULC Reports Third Quarter 2023 Financial Results","summary":"Fulcrum Therapeutics reported its third quarter 2023 financial results, with a net loss of $24.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"FULC Announces Collaboration with Takeda Pharmaceutical","summary":"Fulcrum Therapeutics announced a collaboration with Takeda Pharmaceutical to develop and commercialize Loxo-305 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).","drugName":"Loxo-305","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-01","type":"pipeline","source":"simplywall.st","summary":"Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans - simplywall.st","headline":"Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNSGtMS2pJT3VRelY3Qm9MM0o3WmNRdVhMNnppalpuQm12bmRmX2tjajlBNHNGbHNXcTdFZ1NNLW1xWXExQ0w1UkRSYjZkSTdwNS10Y2xqNmVhNkMxbGEwdnAxN2RYYi1pVjJ6WUFPa2FGZkw1X0M1dDVIZEZJcFFFdmpUbm1YSHNMLVllaFF5V1kzU2o0V0xLZTZNb1NrYk9B?oc=5","date":"2026-03-31","type":"regulatory","source":"Investor's Business Daily","summary":"The Surprise FDA Move That Sent Two Biotechs Rallying - Investor's Business Daily","headline":"The Surprise FDA Move That Sent Two Biotechs Rallying - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNa2c5RWVob0UwcGplR2dISkJpNldIUlJNdDRxRVU3aWdFNU4wcFVXcGd0SUVGa2QxdGJfdzNkbmp1Nlk5aVNZWlBWZE9MalY5UXhiaHFFTHljblpNMGdSejd5SUhSaFNTYjRqSVVaems0S3N6TU5jZ0pFWjFrcHBJbE5RbGtDUzBnaEZGeWN5Z1Q5MFlXRkNacDMwUV9tTVNPUnM3a21SRlFsajJaUVp6OFhwMWFrRWdWTFZDQlR2U2E4V01XLVhZVnZhd2tmeUp6QWZjdkh2azZodk9EdktCR1VVUWJFa0hLSU1OVG1TdWJxZHBaTWhNN2o1VF8yYjBCV2VuQWpXOGQ?oc=5","date":"2026-03-31","type":"pipeline","source":"Benzinga","summary":"Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High - Benzinga","headline":"Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQSTg2dEZYTExuNVNJWDZPSE5mSmR1OTNrdzF0Mk9zY3JLQ090VXNNczRIUGJ1NXdtSVdGSlAyNzRqRTZVaV9vOWxhYVBPbWI1d3JESEk4UTJ6ODk2ZWlfU1V1bGw5QWEzY2U5d2pqV0ZIYl96c2FadWpRRzhLdXRBcmUyWjc5R0xlSDctZVNMUlppUGg2NlJublA4NFg5NG50Yk9PWWxhNUpCeUJoVzV3bFZkdUl6RWlxZzRyZ2R3TkdvaG5GV19iQjA0UQ?oc=5","date":"2026-03-26","type":"pipeline","source":"Stock Titan","summary":"Vanguard entities disaggregate Fulcrum holdings (FULC) after internal realignment - Stock Titan","headline":"Vanguard entities disaggregate Fulcrum holdings (FULC) after internal realignment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQLXF0NkpCRzNNU0xYZnhkdUNsbk9Kc3VqajhKZkFuLS01cy14cXd0WTdRU082Zi1UU2FnOWVUNmZ5WlBzMzRGWTlEbGNvS0Z4LV9TdGlnQUVic1pyNFNIMFQ3TXpVUGJUd3ZGZnZSWjZxbWZ0NHdnTFE2ODh0UGx3V2k1WnByRkV1ZzdEU3VaZzcxSDRDNjFFM29VT3UyQlhrMVNKRTdTNmtpMkF4YkJaak93TDJHMkZuZ19nVVZxYkluUU1BOE0wejdGX3BIbkJZdDR6ZUdEX04zUQ?oc=5","date":"2026-03-22","type":"pipeline","source":"marketscreener.com","summary":"Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com","headline":"Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPRDktbGlkZkVidkE4a0RJQkhlei1rUjB2aEEyYzFYQnhTSWIzc1MxRzQyX0J1YlVBRHotM1hHM2hENURvRWNfVHd4dnNBZzZldklILXUzMEpsYlN6cERYc3NzbnNUSWFNZUx4dnBwb0FmcHU3UVE0d1VCNTVJMFBMV2NCakJodVlDUjNHZFhDckhwT3N4WEhKeU1ITEN2bW9zRjBfQkVZNEJXbkNnOTJ5MEZiME1CeklJVFJub0puOE1xT1RRelhTRkxMdV91VmhwZ284TTBnb1VDakh1Q2h5U0tJd0hPd09HRDVmX3l2cmEzWXF3YkZDQ1lGc3JuT3ZPN0hpQ0JZeHJWZFZmRzkwYmE3ZVgzV2hp?oc=5","date":"2026-02-24","type":"pipeline","source":"globenewswire.com","summary":"Fulcrum Therapeutics Announces Recent Business Highlights - globenewswire.com","headline":"Fulcrum Therapeutics Announces Recent Business Highlights","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPbHBjYS13dGptLWNvUW5WMU9PWWNfOHRwT1VVNHUzLV8zQUlycVBJTFNvaEdTMGRHYnNzNDU2YVd6X1BjQzYtajl1ckwwNFNhZkY3TVU2aG80RDhfbndFSXg4QUpvSmdFWkNJZEd2RDUxS1NHUktGZ3M1ZzZncDRzWl9FVXVvWlF3UmFUWXVXR2F6X3piY2JUS3J1MUJHbG90eDNDcmZxaEJZaFZ2dV9CcUNjZGxaV0pPaHc?oc=5","date":"2025-12-10","type":"pipeline","source":"Stock Titan","summary":"Fulcrum Therapeutics (Nasdaq: FULC) sets $13.50 price for 11,851,853-share equity sale - Stock Titan","headline":"Fulcrum Therapeutics (Nasdaq: FULC) sets $13.50 price for 11,851,853-share equity sale","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-09","type":"trial","source":"simplywall.st","summary":"Fulcrum Therapeutics (FULC): Valuation Check After PIONEER Trial Success and Follow-On Offering - simplywall.st","headline":"Fulcrum Therapeutics (FULC): Valuation Check After PIONEER Trial Success and Follow-On Offering","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPTmtNZk1YdDF4Tk1acEdfZ0diNTByeVZCcUZyZnptaG5pejk0RmlWTzRiWDlnZjAtd0dfZVpEZVl0NlNOUnhlNmdaZFdxc2F2dFlHOGRaVnllMVJNYkxBQU1ZMkFGR0lUNXBSaGN0amtXZ21uNEpmWTlqQzhVbU5hTjBLVThOOVN0cDJBVnh6ODJ3UGEzelN5Qks1dXZwbFRMX1NIa092Q3RxQVNZQXd0by1GWkU3emFDcDZLTmlESzNUb0E4b2Nz?oc=5","date":"2025-12-08","type":"deal","source":"TechStock²","summary":"Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025) - TechStock²","headline":"Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025) - TechS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQblRiNnhycWJHNGM0NjBnWWVyYVBsbTlpMEtpdzdCcmhsSXlxWlhGeFk0UV9EblJkb0lJdUlCYlBEN0c3TFBZVVVRd3BQa3BIaDRHN2pUMm8zYk9ZMFJfTFBYYUlVcmpyQ0ZRQjdGVGJUTm5IMDUtQ1VzWEEzR0thbXo1a0pEb2l3RXZSemE2dGRRenpoM2Nhb3RGaGVPSm1nT3FIUlc5eTdiTC1TUzNLMjI1QjBxN2NCSjZwY0FzTQ?oc=5","date":"2025-12-05","type":"pipeline","source":"Stock Titan","summary":"Fulcrum Therapeutics (Nasdaq: FULC) issues options at $9.87 under 2022 inducement plan - Stock Titan","headline":"Fulcrum Therapeutics (Nasdaq: FULC) issues options at $9.87 under 2022 inducement plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOVzhQV1NVTnJTN015bDZaNXlZQVBlZVhoMGo3YnJJbzJoa0NPQS1sZzgwOWhNOHVlS2JQdnpzY1pBendzYUVsb0N1UF9MNkZkRVR2N1FKODRTU1hKWDBHTGJzcWpfVlFjSTZvNHFQZGt4SFV0dFdCTHViOGlQTERuOERmTVV4ZllVWGdSXzBHME16XzJ6NnhYeGwydmpQR0FfYTNn?oc=5","date":"2025-11-19","type":"pipeline","source":"Investor's Business Daily","summary":"This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily","headline":"This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Pfizer","Biogen","Sarepta Therapeutics"],"therapeuticFocus":["Rare Diseases","Neuromuscular Disorders"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":56103000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-74880000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":366284000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}